Journal of the American College of Cardiology
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Andrew Wang, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Michael E Nassif, Maria Luisa Peña-Peña, Roberto Barriales-Villa, Ozlem Bilen, Melissa Burroughs, Brian L Claggett, Juan Pablo Costabel, Edileide de Barros Correia, Anne Dybro, Perry Elliott, Sheila M Hegde
Published: 202510.1016/j.jacc.2025.10.057
Abstract
BACKGROUND: For >60 years, beta-blockers have been first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), although limited data support this recommendation. The MAPLE-HCM trial showed greater improvement in exercise capaci…
Preview only. Read the full abstract at the source